Amoxicillin/clavulanate potassium is a prescription combination antibiotic containing amoxicillin, a penicillin-class antibacterial, and clavulanate potassium, a beta-lactamase inhibitor. In the United States, FDA-approved generic products are marketed under established names such as amoxicillin and clavulanate potassium rather than necessarily using the Augmentin brand name. The combination is distinct from plain amoxicillin because it contains two active components, and the clavulanate component affects activity against certain beta-lactamase-producing bacteria. A pharmacy listing for amoxicillin alone must not be confused with a combination product.
Generic amoxicillin/clavulanate products include conventional oral tablets, chewable tablets and powders prepared as oral suspensions. Product labels identify both active-component quantities, not simply the amount of amoxicillin. For example, an 875 mg/125 mg combination tablet has a different identity from a plain 875 mg amoxicillin tablet, and a 250 mg/125 mg conventional combination tablet is not equivalent to a 250 mg/62.5 mg chewable presentation. Related branded products such as Augmentin XR and Augmentin ES-600 introduce additional release or concentration distinctions that cannot be ignored when evaluating generic products.
For a U.S. prescription buyer, the central verification task is to determine whether the actual dispensed medicine matches the prescribed active ingredients, dosage form, strength and applicable substitution requirements. FDA approval records, abbreviated new drug applications, therapeutic-equivalence evaluations and published product labeling provide different parts of this evidence. None independently guarantees current pharmacy inventory, insurance coverage or suitability for a particular patient. This guide focuses on generic product identity and regulatory verification; the Augmentin brand guide covers branded formulations, while the manufacturer directory and dedicated pricing pages address their respective questions.
Generic amoxicillin/clavulanate is a two-ingredient antibacterial medicine. The pharmaceutical components are amoxicillin, commonly present as amoxicillin trihydrate, and clavulanic acid supplied as clavulanate potassium. Amoxicillin inhibits bacterial cell-wall synthesis in susceptible organisms. Clavulanate inhibits certain beta-lactamase enzymes that can otherwise inactivate amoxicillin, although it does not overcome every bacterial resistance mechanism.
The names amoxicillin/clavulanate, amoxicillin and clavulanate potassium, and generic Augmentin are often used when discussing this combination. The precise established name appears in the relevant product labeling, while Augmentin is a proprietary brand associated with certain FDA-approved combination formulations. In pharmacy searches, generic Augmentin is a common shorthand, but it is not a substitute for checking the actual drug product and its FDA approval information.
A generic combination medicine should not be confused with two separately supplied prescription products or with amoxicillin alone. An ordinary amoxicillin tablet does not contain clavulanate. Likewise, the presence of clavulanate in a combination product does not automatically make it preferable for every bacterial infection. The appropriate antibacterial agent depends on the infection, organism susceptibility, clinical findings and individual medical considerations.
The distinction is particularly important because U.S. pharmacies and prescription software may display both brand and established drug names. A search result can use the brand name as a familiar reference while the actual dispensed package identifies amoxicillin and clavulanate potassium. The pharmacy label, approved product identity and dispensing record should resolve which medicine has actually been supplied.
For readers specifically comparing the two different antibacterial medicines, the Augmentin vs amoxicillin comparison explains why adding clavulanate changes the product identity without establishing that the combination is universally more appropriate.
Conventional generic amoxicillin/clavulanate products are available in several FDA-labeled oral dosage forms. These include film-coated immediate-release tablets, chewable tablets and powders for oral suspension. Individual FDA-approved generic applications and product labels determine which specific forms and strengths are associated with a particular product. The complete set of labeled combination presentations should not be interpreted as a statement that every generic manufacturer markets every strength.
Conventional immediate-release tablets commonly contain 250 mg/125 mg, 500 mg/125 mg or 875 mg/125 mg of amoxicillin and clavulanic acid, respectively. The second number is not an incidental detail: the amount of clavulanate changes the identity of the strength pair. A reader examining a tablet listing should therefore check both numbers, the dosage form and the actual approved product.
Chewable generic products have their own labeled strengths, including presentations containing 125 mg/31.25 mg, 200 mg/28.5 mg, 250 mg/62.5 mg and 400 mg/57 mg. Their proportions are not automatically equivalent to those of conventional tablets. In addition, generic chewables can have formulation-specific inactive ingredients, flavorings, appearance and instructions that should be checked against the dispensed product label.
Generic oral suspensions are typically supplied as powders requiring reconstitution before use. Their labeled concentrations include 125 mg/31.25 mg, 200 mg/28.5 mg, 250 mg/62.5 mg and 400 mg/57 mg per 5 mL. A concentration per 5 mL describes the prepared medicine, not the amount in a dry powder bottle before preparation. Bottle sizes, supplied powder quantities, manufacturer instructions and storage directions can differ by product.
Product-specific details about conventional combination tablets are covered in the amoxicillin/clavulanate tablet product guide. Readers evaluating liquid formulations can consult the combination oral suspension guide for more detailed concentration and package-identification information.
| Generic dosage form | FDA-labeled strength pairs | How the strength is expressed | Important distinction |
|---|---|---|---|
| Conventional oral tablets | 250 mg/125 mg; 500 mg/125 mg; 875 mg/125 mg | Amoxicillin mg / clavulanic acid mg per tablet | Immediate-release combination tablets; not plain-amoxicillin products. |
| Chewable tablets | 125 mg/31.25 mg; 200 mg/28.5 mg; 250 mg/62.5 mg; 400 mg/57 mg | Amoxicillin mg / clavulanic acid mg per chewable tablet | Different component ratios and formulation characteristics from conventional tablets. |
| Powder for oral suspension | 125 mg/31.25 mg; 200 mg/28.5 mg; 250 mg/62.5 mg; 400 mg/57 mg per 5 mL | Amoxicillin mg / clavulanic acid mg per 5 mL after reconstitution | Concentration and prepared-liquid volume must both be identified. |
Combination-drug strengths must be read differently from strengths for single-ingredient medicines. In an amoxicillin/clavulanate product, the first number identifies the amoxicillin amount and the second identifies clavulanic acid supplied as clavulanate potassium. The label expresses these quantities separately because both components contribute to the product's pharmaceutical identity.
For example, a conventional 500 mg/125 mg tablet contains 500 mg of amoxicillin and 125 mg of clavulanic acid. A conventional 250 mg/125 mg tablet contains less amoxicillin but the same amount of clavulanate. Therefore, two 250 mg/125 mg tablets would provide a different total amount of clavulanate than one 500 mg/125 mg tablet. FDA labeling specifically warns against treating those presentations as interchangeable.
Differences become even more apparent when comparing dosage forms. A 250 mg/62.5 mg chewable tablet contains the same nominal amoxicillin amount as a 250 mg/125 mg conventional tablet, but only half as much clavulanic acid. Their component ratios are different. Matching the first strength number does not establish equivalence.
The FDA permits certain substitutions among standard immediate-release tablets, chewable tablets and oral suspensions when the component ratio and other specific requirements match. Those permissions are limited and should not be generalized to every product bearing the combination's established name. Any change in form, concentration or number of units requires appropriate professional review and must comply with the product labeling and prescription.
A patient comparing package labels should therefore consider the two active-component amounts as a pair rather than treating clavulanate as an optional secondary ingredient. The labeled pair, release characteristics and dosage form matter more than an approximate total milligram value.
| Illustrative labeled presentation | Amoxicillin content | Clavulanic acid content | Interpretation |
|---|---|---|---|
| Conventional 250 mg/125 mg tablet | 250 mg per tablet | 125 mg per tablet | A 2:1 component ratio; not equivalent to the 250 mg/62.5 mg chewable tablet. |
| Conventional 500 mg/125 mg tablet | 500 mg per tablet | 125 mg per tablet | A 4:1 component ratio; cannot be reproduced by taking two 250 mg/125 mg tablets. |
| Conventional 875 mg/125 mg tablet | 875 mg per tablet | 125 mg per tablet | A 7:1 component ratio; distinct from a plain 875 mg amoxicillin tablet. |
| 400 mg/57 mg suspension | 400 mg per 5 mL | 57 mg per 5 mL | Approximately a 7:1 component ratio; liquid concentration is not a tablet-strength instruction. |
Augmentin is a proprietary brand name associated with amoxicillin/clavulanate combination products. An independently approved generic typically uses the established active-ingredient name on its labeling and is approved through an abbreviated new drug application. The regulatory question is whether that generic meets the FDA requirements applicable to its reference product, not whether the package visually resembles the original brand.
For an ANDA approval, the applicant generally relies on the FDA's previous finding of safety and effectiveness for a reference listed drug while demonstrating the required pharmaceutical equivalence, bioequivalence and other regulatory conditions. A qualifying generic is expected to meet applicable standards for identity, strength, quality and performance. However, inactive ingredients, manufacturer-specific tablet appearance, packaging and certain labeling details may differ within regulatory limits.
The distinction between a brand and an approved generic does not mean that all amoxicillin/clavulanate products are automatically substitutable. Therapeutic-equivalence determinations apply to particular approved products and their relevant reference relationships. A conventional immediate-release product should not be treated as equivalent to an extended-release product merely because both contain amoxicillin and clavulanate.
Authorized generics require a separate explanation. An authorized generic is a drug marketed without the brand name under the brand's approved new drug application rather than an independently approved ANDA. Thus, a pharmacy listing showing an established drug name does not, by itself, establish whether the product is an ANDA generic or an authorized generic. The actual approval category needs verification.
A dedicated Augmentin vs generic comparison examines the brand-to-generic relationship in more detail, including approved product identity and what may legitimately differ between packages. This page concentrates on the generic combination category itself rather than the complete history or marketing identity of the Augmentin brand.
The FDA Orange Book is a central regulatory resource for identifying approved drug products and applicable therapeutic-equivalence evaluations. For generic amoxicillin/clavulanate, it helps distinguish products approved under abbreviated new drug applications from reference products approved under new drug applications. The database can also identify relevant dosage forms, strengths, application holders and therapeutic-equivalence codes where assigned.
An ANDA number identifies a regulatory application rather than a retail product guarantee. The existence of an approved application does not establish that every historically approved strength remains marketed, that a particular manufacturer supplies a current pharmacy, or that a displayed NDC is presently in commercial distribution. Approval status, marketing status and retail availability must be evaluated separately.
An FDA therapeutic-equivalence evaluation provides more specific information than a broad statement that two medicines contain the same ingredients. Where the Orange Book identifies qualifying products as therapeutically equivalent, that evaluation concerns the specified approved products under FDA criteria. It does not authorize patients to change strengths, alter release characteristics or replace one formulation with another without professional oversight.
DailyMed supplies another important layer of information through published Structured Product Labeling records. These records may identify the product name, dosage form, ingredient strengths, labeler, package information, NDCs and marketing category. A DailyMed marketing-status field can help distinguish an ANDA product from an authorized generic marketed under an NDA, but the FDA's underlying approval records remain important for confirmation.
A complete product review often involves more than one database. An Orange Book entry can establish an approval relationship, while a current labeling record can help identify the marketed package. The prescribing professional and dispensing pharmacist remain responsible for determining whether a specific medicine is appropriate and may lawfully be dispensed.
Readers seeking a detailed walkthrough of approval records can consult the FDA-approved amoxicillin/clavulanate products guide. That page owns the deeper examination of approval records, regulatory listings and reference-product relationships.
| Regulatory identifier | What it establishes | What it does not establish |
|---|---|---|
| NDA | A new drug application and its FDA approval relationship. | Current retail availability or automatic interchangeability with all related products. |
| ANDA | An abbreviated new drug application for a generic product meeting applicable FDA requirements. | That every strength or package is currently marketed or locally stocked. |
| Orange Book therapeutic-equivalence code | FDA's evaluation for specified approved products where an applicable code is assigned. | Permission to substitute across unrelated strengths, dosage forms or release types. |
| DailyMed SPL record | Published product-label information, potentially including ingredients, dosage form, labeler and package identifiers. | Independent confirmation of a patient's prescription or real-time pharmacy inventory. |
| NDC | A drug-product and package identifier associated with the relevant labeler and listing. | FDA approval by itself, clinical suitability, authenticity or guaranteed availability. |
Generic amoxicillin/clavulanate products may appear under different manufacturer, distributor, labeler or repackager names. These entities do not always perform the same function. The company holding an approved ANDA may be different from the entity identified as a distributor or labeler on a pharmacy package. A repackaged product may also display a different NDC from its source package.
As a result, a manufacturer name in a search result should not automatically be treated as proof of the underlying approval holder or the physical production site. Identifying a generic product accurately may require matching the application information with the actual published label, dosage form, strength, package identifier and relevant marketing details.
Tablet color, shape and imprint can also vary between approved generic products. These characteristics can help distinguish physical packages, but visual resemblance is not a reliable substitute for official identification. A photograph of an unlabeled tablet cannot establish FDA approval, ingredient strength or suitability for a prescription.
A brand name appearing on an older label, an authorized-generic record or a repackaged product should be interpreted in its regulatory context. Historical records and current pharmacy supply represent different questions. Patients should ask the dispensing pharmacist to identify the actual supplied medicine if the manufacturer or package differs from expectations.
The dedicated amoxicillin/clavulanate generic manufacturers directory addresses applicant, manufacturer and labeler distinctions in greater depth. Manufacturer-specific catalogs and company profiles belong there rather than being duplicated in this general generic-product guide.
The shared active ingredients in amoxicillin/clavulanate products do not eliminate differences between release technologies and formulations. Standard combination tablets are immediate-release products. Augmentin XR is a separately identified extended-release product, and Augmentin ES-600 is a specialized oral suspension with a different component proportion. These distinctions must remain visible when evaluating generic labels and pharmacy records.
Augmentin XR tablets contain 1,000 mg of amoxicillin and 62.5 mg of clavulanic acid per tablet. Their extended-release characteristics distinguish them from conventional immediate-release tablets. A conventional 500 mg/125 mg tablet cannot simply be exchanged for an XR tablet by comparing or multiplying amoxicillin totals. The FDA label explicitly rejects certain such substitutions.
Augmentin ES-600 suspension contains 600 mg of amoxicillin and 42.9 mg of clavulanic acid per 5 mL after reconstitution. It has formulation-specific pediatric indications and handling considerations. Standard 400 mg/57 mg per 5 mL combination suspension is a different concentration and component proportion, not an interchangeable presentation based solely on the shared active ingredients.
The existence of a branded XR or ES-600 reference product does not establish that an independently approved, therapeutically equivalent generic version is currently marketed. Such claims require product-specific verification through FDA approval records and applicable marketing information. The established name amoxicillin and clavulanate potassium is not sufficient to prove equivalence across these formulations.
This distinction is particularly important in online catalogs that group immediate-release tablets, oral liquids and related branded products under a common search term. A prospective buyer should not assume that a product recommendation, generic dropdown option or search-filter match authorizes a change from the prescribed formulation.
For a closer examination of the brand product identities, see the Augmentin XR guide and the Augmentin ES-600 guide. Those pages address the specialized formulations without converting this generic hub into a duplicate brand catalog.
A U.S. pharmacy must process amoxicillin/clavulanate as a prescription medicine. The first question is whether a valid prescription identifies the intended medication and relevant formulation. Product selection is a clinical and dispensing matter, not something that can be established merely by choosing a strength from an online product catalog.
The pharmacy should confirm the prescribed active ingredients, dosage form, component strengths and directions. If a brand-name prescription is being dispensed as a generic, the pharmacist must also consider the applicable therapeutic-equivalence information, prescription restrictions and state substitution requirements. An independently approved generic should not be confused with an authorized generic solely because both may appear under nonproprietary names.
The dispensed container label provides practical identification information. Depending on the product and pharmacy labeling conventions, this may include the established or proprietary drug name, strength, dosage form, manufacturer or labeler, directions, quantity and other dispensing information. The NDC can help identify the packaged product, but it is not independent proof of approval, clinical appropriateness or present inventory.
If the prescription requests an oral suspension, the concentration and preparation status require additional attention. A listing for powder for oral suspension does not necessarily represent a ready-to-use liquid. Reconstitution, final concentration, storage conditions and product-specific instructions must be established by the dispensing pharmacy. Standard amoxicillin/clavulanate suspension labels generally require refrigerated storage after reconstitution and specify a limited period of use.
The actual pharmacy quote should correspond to the product being dispensed, not merely a similar ingredient name. An online pharmacy may display several strength pairs or historic package options without having each one available. Product approval records and NDC listings do not replace direct inventory confirmation or professional prescription review.
Questions about lawful prescription-based purchasing are addressed in the U.S. Augmentin and generic combination buying guide. That separate page covers access pathways, while this guide concentrates on generic drug identity and verification.
| Pharmacy check | Information to reconcile | Reason for checking |
|---|---|---|
| Active ingredients | Amoxicillin plus clavulanate potassium | Prevents confusion with plain amoxicillin products. |
| Dosage form | Immediate-release tablet, chewable tablet or oral suspension | Different formulations may have different labeling and substitution rules. |
| Strength pair | Both amoxicillin and clavulanic acid amounts | Matching only the amoxicillin number can identify the wrong product. |
| Approval relationship | ANDA, NDA or authorized-generic context when relevant | Helps establish the correct regulatory product identity. |
| Labeler and NDC | Actual package identifiers supplied by the dispensing pharmacy | Helps distinguish marketed or repackaged products. |
| Prescription and substitution | Valid prescription, applicable state rules and product equivalence | A generic name alone does not authorize unrestricted substitution. |
| Pharmacy supply | Whether the particular approved product can actually be dispensed | Regulatory records do not establish current inventory. |
Generic amoxicillin/clavulanate has the same active antibacterial components as the corresponding reference combination product. Patients should therefore consider the important warnings, precautions and contraindications in the applicable FDA-approved labeling. A generic package is not inherently safer or less potent simply because it lacks a familiar brand name.
Serious hypersensitivity reactions are a central safety concern. Amoxicillin belongs to the penicillin class, and the combination is contraindicated in patients with a history of serious hypersensitivity reactions to the product or other beta-lactam antibacterial drugs as specified in the labeling. The label also identifies previous amoxicillin/clavulanate-associated cholestatic jaundice or hepatic dysfunction as a contraindication.
Commonly reported adverse reactions include gastrointestinal effects such as diarrhea, nausea and vomiting. The prescribing information also describes potentially serious complications, including severe allergic reactions, serious skin reactions, liver injury and Clostridioides difficile-associated diarrhea. Sudden breathing difficulty, throat swelling or other signs of a severe allergic reaction require emergency medical attention.
Medication interactions and patient characteristics may affect the prescribing decision. The labeling discusses clinically relevant considerations involving medications such as probenecid, oral anticoagulants and allopurinol. Kidney function, allergy history and other clinical factors can also affect appropriate prescribing and monitoring. Patients should review their complete medication history with their clinician and pharmacist.
Responsible antibiotic use remains essential regardless of brand or generic status. Amoxicillin/clavulanate does not treat viral infections such as influenza or the common cold. Patients should not take leftover antibiotics, share prescriptions or select a combination antibiotic merely because it seems broader than amoxicillin alone. The appropriate treatment depends on a clinical assessment and, where relevant, organism susceptibility.
Further background about reported penicillin hypersensitivity is available in the penicillin allergy guide. This generic-product page does not assess individual allergy risk or provide personalized treatment recommendations.
Generic amoxicillin/clavulanate products and brand-name Augmentin can have different cash prices, pharmacy supply arrangements and insurance treatment. However, the term generic does not guarantee the lowest possible price in every transaction. Actual costs depend on the prescribed strength, dosage form, quantity, pharmacy, insurance benefits and any applicable discount arrangement.
Pharmacy advertisements sometimes group multiple manufacturers or strengths under a single medicine name. A displayed starting price may refer to a different strength, quantity or dosage form from the prescribed product. Generic tablet prices should not be assumed to describe oral suspensions, specialized formulations or brand-name packages.
Current availability also varies independently of FDA approval status. A particular generic may be listed in the Orange Book and have published labeling while not being stocked by a selected pharmacy. A pharmacy may offer an alternative approved product when legally and clinically appropriate, but any change must respect the prescription and applicable substitution requirements.
For detailed comparisons of generic cost factors, see the generic amoxicillin/clavulanate price guide. This page intentionally avoids unverified quotations, promises of stock, guaranteed prescription approval or assumptions about insurance coverage.
Amoxicillin/clavulanate potassium is a prescription combination antibiotic containing amoxicillin, a penicillin-class antibacterial, and clavulanate potassium, a beta-lactamase inhibitor. It is used for specified infections caused by susceptible bacteria when prescribed by a healthcare professional.
Amoxicillin and clavulanate potassium is the established ingredient name used for generic products corresponding to appropriate Augmentin reference formulations. FDA-approved generics must meet applicable requirements for their specific products. Not every medicine containing these ingredients is interchangeable with every Augmentin formulation.
No. Plain amoxicillin contains amoxicillin without clavulanate. Amoxicillin/clavulanate contains two active components and may retain activity against certain beta-lactamase-producing bacteria. The combination is not automatically preferable to plain amoxicillin for every infection.
Conventional immediate-release tablet strengths include 250 mg/125 mg, 500 mg/125 mg and 875 mg/125 mg. The numbers refer to amoxicillin and clavulanic acid, respectively. A specific generic manufacturer's approved and currently marketed strengths must be checked separately.
The first number identifies the amount of amoxicillin, while the second identifies the amount of clavulanic acid supplied as clavulanate potassium. Both amounts matter because different products can contain the same quantity of amoxicillin but different quantities of clavulanate.
No. A conventional 250 mg/125 mg tablet contains 125 mg of clavulanic acid, while a 250 mg/62.5 mg chewable tablet contains 62.5 mg. The FDA labeling identifies these presentations as not substitutable. Patients should not change between them independently.
Yes. FDA-labeled generic combination products include powders for oral suspension with different amoxicillin and clavulanate concentrations per 5 mL after reconstitution. The prescribed concentration, manufacturer instructions and actual pharmacy supply must be verified.
An FDA-approved generic that meets the applicable pharmaceutical-equivalence and bioequivalence requirements is expected to provide the same clinical benefits and risks as its reference product when used appropriately. This does not establish interchangeability between different strengths, release types or formulations.
An Abbreviated New Drug Application is the FDA regulatory pathway commonly used for generic drugs. An approved ANDA establishes that the product met the applicable approval requirements, including requirements related to its reference drug. Approval alone does not guarantee that the product is currently distributed or stocked.
The FDA Orange Book provides approved-product and applicable therapeutic-equivalence information. It can help identify reference products, ANDA-approved generics, strengths, dosage forms and relevant equivalence evaluations. It is not a real-time pharmacy inventory database.
An independently approved generic is ordinarily approved through an ANDA. An authorized generic is marketed without the brand name under the brand drug's approved NDA. Both may use an established ingredient name on their labels, so the approval category should be checked rather than inferred from packaging alone.
Not automatically. Augmentin XR is an extended-release formulation with distinct release characteristics and strength proportions. A conventional immediate-release generic tablet cannot simply replace XR based on the shared active ingredients or an approximate amoxicillin total. Product-specific regulatory and prescribing requirements apply.
No unrestricted interchangeability should be assumed. Augmentin ES-600 contains 600 mg of amoxicillin and 42.9 mg of clavulanic acid per 5 mL and is a distinct formulation. Standard combination suspensions have different concentrations and component proportions. Changes require professional assessment.
Check the container label and ask the pharmacist to confirm the actual ingredients, strength pair, dosage form, manufacturer or labeler and NDC when applicable. FDA approval and labeling information can help establish product identity, but the dispensing pharmacy must confirm what was actually supplied.
No. Generic amoxicillin/clavulanate is a prescription-only antibacterial medicine in the United States. Lawful dispensing requires a valid prescription and compliance with applicable pharmacy requirements. Online listings promising prescription-free access should not be treated as legitimate substitutes for clinical evaluation.
Not necessarily. Generic products are often priced differently from branded products, but actual out-of-pocket costs depend on strength, form, quantity, pharmacy, insurance benefits and applicable discounts. Current prices must be verified for the specific prescription.
No. Leftover antibiotics should not be used to self-treat a new illness. Symptoms may be caused by a virus or by bacteria requiring a different treatment. An appropriate clinical evaluation is necessary, and unnecessary antibacterial use can cause adverse effects and contribute to resistance.
Amoxicillin is a penicillin-class antibiotic. The combination is contraindicated in patients with a history of serious hypersensitivity reactions to the product or other beta-lactam antibacterial drugs as specified in its labeling. A reported allergy requires professional evaluation before treatment.